| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/JTO.0000000000000693 |
| P698 | PubMed publication ID | 26743856 |
| P50 | author | James Chih-Hsin Yang | Q37840097 |
| Tony Mok | Q61820649 | ||
| P2093 | author name string | Li Zhang | |
| Yan Sun | |||
| Filippo de Marinis | |||
| Luis Paz-Ares | |||
| Vera Hirsh | |||
| Yi-Long Wu | |||
| Egbert F Smit | |||
| Heather A Wakelee | |||
| Silvia Novello | |||
| Teng Jin Ong | |||
| Thomas Schmelter | |||
| Takashi Seto | |||
| Carol Peña | |||
| Erszébet Juhász | |||
| Osvaldo Arén | |||
| P433 | issue | 12 | |
| P921 | main subject | lung cancer | Q47912 |
| phase III clinical trial | Q42824827 | ||
| placebo-controlled trial | Q108853737 | ||
| placebo | Q269829 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 1745-1753 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
| P1476 | title | Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lun | |
| P478 | volume | 10 |
| Q38603815 | Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer |
| Q92249512 | Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report |
| Q47095393 | Angiogenesis Inhibitors in NSCLC. |
| Q50041855 | Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). |
| Q55168137 | Antiangiogenic therapies in non-small-cell lung cancer. |
| Q47345810 | Associations between abnormal vitamin D metabolism pathway function and non-small cell lung cancer |
| Q38641871 | Bevacizumab in advanced lung cancer: state of the art. |
| Q57456582 | Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials |
| Q92912520 | China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy |
| Q99603571 | Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response |
| Q47305390 | Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. |
| Q96133162 | Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study |
| Q38737416 | Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments |
| Q41204382 | Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. |
| Q37583786 | Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies |
| Q49787333 | Implications of KRAS mutations in acquired resistance to treatment in NSCLC. |
| Q28079328 | Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients |
| Q49887897 | KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target |
| Q89303329 | Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine |
| Q52668159 | Newly developed anti-angiogenic therapy in non-small cell lung cancer |
| Q53127741 | Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? |
| Q38936376 | Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations |
| Q90287344 | Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer |
| Q41593429 | Strategies targeting angiogenesis in advanced non-small cell lung cancer |
| Q43298298 | Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells. |
| Q38799845 | Targeting the KRAS Pathway in Non-Small Cell Lung Cancer |
| Q42382909 | The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer |
| Q39134733 | The changing landscape of clinical trial and approval processes in China. |
| Q48223594 | Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. |
Search more.